Christopher D. Hillyer
Research Subjects
Research Interests
Christopher D. Hillyer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Cassandra D. Josephson
From the Pediatric Transfusion Medicine Academic Awardees Program (PedsTMAA)
3 shared publicationsA.J. Grindon
Transfusion Medicine Program, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
1 shared publicationAnne M. Winkler
1 shared publication- Beth Huizenga Shaz
Duke University
1 shared publication Christine B. Kost
From the Transfusion Medicine Program, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
1 shared publicationDaniel R. Ambruso
From the Pediatric Transfusion Medicine Academic Awardees Program (PedsTMAA)
1 shared publication
Latest Publications
- 13 February 2009
- Published by Wiley in Transfusion
- Vol. 49 (3) , 596-601
Pediatric transfusion medicine: development of a critical mass
Many significant events have occurred in the recent past that beg a broad audience to address the question “What is pediatric transfusion medicine?” Herein, we list some of these events and their relevance below and attempt to provide an answer for this question. Indeed, several issues regarding the subspecialty of pediatric transfusion medicine (PTM) are particularly timely, and it appears that a critical mass, or a nidus capable of becoming a critical mass, is developing in PTM.
- 13 February 2009
- Published by Wiley in Transfusion
- Vol. 49 (3) , 596-601
Pediatric transfusion medicine: development of a critical mass
Many significant events have occurred in the recent past that beg a broad audience to address the question “What is pediatric transfusion medicine?” Herein, we list some of these events and their relevance below and attempt to provide an answer for this question. Indeed, several issues regarding the subspecialty of pediatric transfusion medicine (PTM) are particularly timely, and it appears that a critical mass, or a nidus capable of becoming a critical mass, is developing in PTM.
- 29 July 2008
- Published by Wiley in Transfusion
- Vol. 48 (8) , 1530-1537
Transfusion recipient epidemiology and outcomes research: possibilities for the future
The National Heart, Lung, and Blood Institute (NHLBI) supports major research programs related to the field of transfusion medicine, which encompass blood banking, the practice of transfusion medicine itself, and cellular therapies. Specific programmatic elements have included 1) the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN) charged with conducting clinical trials in transfusion medicine and hemostasis; 2) the Retrovirus Epidemiology Donor Study–II (REDS‐II), which includes domestic and international efforts dedicated to blood donor safety and blood availability issues; 3) the Specialized Centers of Clinically Oriented Research (SCCOR) in Transfusion Biology and Medicine that include two major projects, the Biologic and Immunologic Aspects of Transfusion Medicine Program and the Transfusion and Lung Injury Program, and 4) the Transfusion Therapy Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS), a Phase III clinical trial that has as its major goal to determine whether a more aggressive transfusion strategy in surgery patients with cardiovascular disease (or risk factors) is associated with improved functional recovery and decreased risk of adverse postoperative outcomes. Notably, none of these programs supports epidemiologic and clinical outcomes research focused on transfusion recipients. Thus, on October 31, 2007, a Working Group on Transfusion Recipient Epidemiology and Outcomes Research was convened by the NHLBI. This group was asked to discuss the current status of the field, identify critical research needs, and make recommendations to the NHLBI program staff.
- 29 July 2008
- Published by Wiley in Transfusion
- Vol. 48 (8) , 1530-1537
Transfusion recipient epidemiology and outcomes research: possibilities for the future
The National Heart, Lung, and Blood Institute (NHLBI) supports major research programs related to the field of transfusion medicine, which encompass blood banking, the practice of transfusion medicine itself, and cellular therapies. Specific programmatic elements have included 1) the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN) charged with conducting clinical trials in transfusion medicine and hemostasis; 2) the Retrovirus Epidemiology Donor Study–II (REDS‐II), which includes domestic and international efforts dedicated to blood donor safety and blood availability issues; 3) the Specialized Centers of Clinically Oriented Research (SCCOR) in Transfusion Biology and Medicine that include two major projects, the Biologic and Immunologic Aspects of Transfusion Medicine Program and the Transfusion and Lung Injury Program, and 4) the Transfusion Therapy Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS), a Phase III clinical trial that has as its major goal to determine whether a more aggressive transfusion strategy in surgery patients with cardiovascular disease (or risk factors) is associated with improved functional recovery and decreased risk of adverse postoperative outcomes. Notably, none of these programs supports epidemiologic and clinical outcomes research focused on transfusion recipients. Thus, on October 31, 2007, a Working Group on Transfusion Recipient Epidemiology and Outcomes Research was convened by the NHLBI. This group was asked to discuss the current status of the field, identify critical research needs, and make recommendations to the NHLBI program staff.
- 1 April 2008
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 22 (2) , 117-132
Integrating Molecular Technologies for Red Blood Cell Typing and Compatibility Testing Into Blood Centers and Transfusion Services
- 1 April 2008
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 22 (2) , 117-132
Integrating Molecular Technologies for Red Blood Cell Typing and Compatibility Testing Into Blood Centers and Transfusion Services
- 1 June 2007
- Published by Wiley in Transfusion
- Vol. 47 (8) , 1412-1417
Nonfatal intravascular hemolysis in a pediatric patient after transfusion of a platelet unit with high‐titer anti‐A
BACKGROUND: In the pediatric population, hemolysis after out‐of‐group platelet (PLT) transfusion is a potentially fatal event that is thought to be underrecognized. Group A patients transfused with group O single‐donor PLTs (SDPs) with “high‐titer” anti‐A are at greatest risk for hemolysis.STUDY DESIGN AND METHODS: A clinical and serologic evaluation of a pediatric patient with hemolysis of initially unknown etiology was conducted. Retrospective testing for anti‐A titer of an admission sample and a transfused group O SDP was performed.RESULTS: The group A patient (previously group O) was found to have a history of engrafted major ABO‐mismatched hematopoietic peripheral blood progenitor cell transplant (HPBPCT). Immune‐mediated intravascular hemolysis with a delayed presentation was determined. Testing identified passive anti‐A in the patient's plasma and high‐titer anti‐A (IgG 4096, IgM 256) in the group O SDP unit.CONCLUSION: Hemolysis after out‐of‐group SDP transfusion may be delayed in presentation and, thus, clinically unrecognized. When evaluating these cases, the limitations of routine type and screen for detection of passive anti‐A must be considered. Group A individuals with a history of engrafted major ABO‐mismatched HPBPCT potentially have increased susceptibility to hemolysis from group O SDP transfusion due to their lack of tissue and soluble A antigen.
- 1 June 2007
- Published by Wiley in Transfusion
- Vol. 47 (8) , 1412-1417
Nonfatal intravascular hemolysis in a pediatric patient after transfusion of a platelet unit with high‐titer anti‐A
BACKGROUND: In the pediatric population, hemolysis after out‐of‐group platelet (PLT) transfusion is a potentially fatal event that is thought to be underrecognized. Group A patients transfused with group O single‐donor PLTs (SDPs) with “high‐titer” anti‐A are at greatest risk for hemolysis.STUDY DESIGN AND METHODS: A clinical and serologic evaluation of a pediatric patient with hemolysis of initially unknown etiology was conducted. Retrospective testing for anti‐A titer of an admission sample and a transfused group O SDP was performed.RESULTS: The group A patient (previously group O) was found to have a history of engrafted major ABO‐mismatched hematopoietic peripheral blood progenitor cell transplant (HPBPCT). Immune‐mediated intravascular hemolysis with a delayed presentation was determined. Testing identified passive anti‐A in the patient's plasma and high‐titer anti‐A (IgG 4096, IgM 256) in the group O SDP unit.CONCLUSION: Hemolysis after out‐of‐group SDP transfusion may be delayed in presentation and, thus, clinically unrecognized. When evaluating these cases, the limitations of routine type and screen for detection of passive anti‐A must be considered. Group A individuals with a history of engrafted major ABO‐mismatched HPBPCT potentially have increased susceptibility to hemolysis from group O SDP transfusion due to their lack of tissue and soluble A antigen.
- 28 June 2004
- Published by Wiley in Transfusion
- Vol. 44 (7) , 977-983
Description and investigation of white particulate matter in additive solution‐1 red blood cell units
BACKGROUND: In January 2003, “white particulate matter” (WPM) was transiently observed in red blood cell (RBC) units collected predominately in the southeastern US. In this report, these events, their chronology, perti‐nent observations and investigations, and summaries and conclusions associated with WPM during the 2‐week observation period are described.CHRONOLOGY AND INVESTIGATIONS: On January 27, 2003, WPM was first identified in RBCs; by January 31, 2003, 110 RBC units containing WPM had been identified. Elective surgeries were postponed. Approxi‐mately 400 RBC units containing WPM were inspected in the blood center and characterized into four types: I, II, III, and IV. A variety of preparations of aspirated WPM were made, including light and electron microscopic sections.RESULTS AND CONCLUSIONS: The rate of WPM‐containing units was 1.67 percent (1 in 60 units), whereas the background incidence was less than 0.25 percent. Investigations revealed that WPM was composed of activated and nonactivated platelets (PLTs); no toxins, infectious agents, or agents of bioterrorism were iden‐tified. WPM correlated with certain variables studied, including PLT‐rich components that had been centrifuged with a “hard spin” before leukoreduction and manu‐factured in one vendor's collection sets. Because the increased rate of appearance of WPM was a transient phenomenon, it is not clear whether this is a newly noticed or a new and different phenomenon from “aggregates” observed in the past.
- 28 June 2004
- Published by Wiley in Transfusion
- Vol. 44 (7) , 977-983
Description and investigation of white particulate matter in additive solution‐1 red blood cell units
BACKGROUND: In January 2003, “white particulate matter” (WPM) was transiently observed in red blood cell (RBC) units collected predominately in the southeastern US. In this report, these events, their chronology, perti‐nent observations and investigations, and summaries and conclusions associated with WPM during the 2‐week observation period are described.CHRONOLOGY AND INVESTIGATIONS: On January 27, 2003, WPM was first identified in RBCs; by January 31, 2003, 110 RBC units containing WPM had been identified. Elective surgeries were postponed. Approxi‐mately 400 RBC units containing WPM were inspected in the blood center and characterized into four types: I, II, III, and IV. A variety of preparations of aspirated WPM were made, including light and electron microscopic sections.RESULTS AND CONCLUSIONS: The rate of WPM‐containing units was 1.67 percent (1 in 60 units), whereas the background incidence was less than 0.25 percent. Investigations revealed that WPM was composed of activated and nonactivated platelets (PLTs); no toxins, infectious agents, or agents of bioterrorism were iden‐tified. WPM correlated with certain variables studied, including PLT‐rich components that had been centrifuged with a “hard spin” before leukoreduction and manu‐factured in one vendor's collection sets. Because the increased rate of appearance of WPM was a transient phenomenon, it is not clear whether this is a newly noticed or a new and different phenomenon from “aggregates” observed in the past.
- 15 December 2000
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 15 (4) , 242-248
Indications for therapeutic plasma exchange at a university hospital and a regional blood center
The AABB guidelines for therapeutic plasma exchange (TPE) are divided into four categories: I. TPE is “standard and acceptable therapy,” II. “generally accepted,” III. “insufficient evidence to evaluate efficacy,” and IV. “data suggest no therapeutic efficacy.” Since little is known about the implementation of these guidelines, and since the indications for TPE may vary, depending upon an institution's patient mix, this study reviewed the indications and their categories for two co‐located institutions. A retrospective review of the indications for all patients undergoing TPE from January 1, 1994 to December 31,1997 at Emory University Hospital (EUH), a tertiary‐care teaching hospital, and the American Red Cross (ARC), a regional blood center, using AABB criteria (ASFA criteria used when not rated [NR] by AABB) was conducted. Categories I/II represented 75% and 88% of cases (EUH and ARC, respectively), while Categories III/IV/NR (NR as used below is “not rated” by both AABB and ASFA criteria; n is number of patients) were 25% and 12% of indications, respectively (P =0.002). Cases at EUH (n=101) were I, 62%; II, 13%; III, 3%; IV, 13%; and NR, 9%. Cases at ARC (n=359) were I, 77%; II, 11%; III, 9%; IV, 0%; and NR, 3% (P < 0.001). No Category IV patients underwent TPE at ARC (13% at EUH). Thrombotic thrombocytopenic purpura (TTP) was the most common indication for TPE at both centers. The majority of the procedures were “appropriate” (Categories III/); several disorders (∼10%) for which TPE was utilized at both centers were NR by both AABB and ASFA guidelines. Indications for TPE may differ, depending on the type of requesting institution. Physicians requesting TPE for patients with disorders in Categories III/IV/NR should be more strongly encouraged to enter their patients into controlled trials to best evaluate the efficacy of TPE in inadequately‐studied clinical situations. This might best be accomplished at university hospitals, where requests for Category III/IV/NR may be higher. A need exists for periodic updating of the AABB guidelines to include those diseases for which new information is available with regard to the potential therapeutic role of TPE. J. Clin. Apheresis 15:242–248, 2000.
- 15 December 2000
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 15 (4) , 242-248
Indications for therapeutic plasma exchange at a university hospital and a regional blood center
The AABB guidelines for therapeutic plasma exchange (TPE) are divided into four categories: I. TPE is “standard and acceptable therapy,” II. “generally accepted,” III. “insufficient evidence to evaluate efficacy,” and IV. “data suggest no therapeutic efficacy.” Since little is known about the implementation of these guidelines, and since the indications for TPE may vary, depending upon an institution's patient mix, this study reviewed the indications and their categories for two co‐located institutions. A retrospective review of the indications for all patients undergoing TPE from January 1, 1994 to December 31,1997 at Emory University Hospital (EUH), a tertiary‐care teaching hospital, and the American Red Cross (ARC), a regional blood center, using AABB criteria (ASFA criteria used when not rated [NR] by AABB) was conducted. Categories I/II represented 75% and 88% of cases (EUH and ARC, respectively), while Categories III/IV/NR (NR as used below is “not rated” by both AABB and ASFA criteria; n is number of patients) were 25% and 12% of indications, respectively (P =0.002). Cases at EUH (n=101) were I, 62%; II, 13%; III, 3%; IV, 13%; and NR, 9%. Cases at ARC (n=359) were I, 77%; II, 11%; III, 9%; IV, 0%; and NR, 3% (P < 0.001). No Category IV patients underwent TPE at ARC (13% at EUH). Thrombotic thrombocytopenic purpura (TTP) was the most common indication for TPE at both centers. The majority of the procedures were “appropriate” (Categories III/); several disorders (∼10%) for which TPE was utilized at both centers were NR by both AABB and ASFA guidelines. Indications for TPE may differ, depending on the type of requesting institution. Physicians requesting TPE for patients with disorders in Categories III/IV/NR should be more strongly encouraged to enter their patients into controlled trials to best evaluate the efficacy of TPE in inadequately‐studied clinical situations. This might best be accomplished at university hospitals, where requests for Category III/IV/NR may be higher. A need exists for periodic updating of the AABB guidelines to include those diseases for which new information is available with regard to the potential therapeutic role of TPE. J. Clin. Apheresis 15:242–248, 2000.